Jubilant Ingrevia Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Pricing bottomed, volumes held the line: Revenue was nearly flat YoY at INR1,051 crore as ~9% volume growth offset softer pricing across all three segments. Management sees pricing as having bottomed out, with early upticks already visible in some products.
• The CDMO pipeline is now a material, disclosed growth engine: 16 confirmed molecules with a peak annual revenue potential of INR1,400 crore plus, and the large agrochemical CDMO plant at Bharuch has been commissioned and will ship its first output in March 2026.
• Nutrition posted its strongest volume quarter in 7 periods, and a price recovery is beginning: Feed-grade vitamin B3 volumes hit a 7-quarter high, and a 7-8% price increase has materialized in the last few days, which management hopes will sustain.
• Margins are under pressure but the company is reinvesting for growth: EBITDA fell 8% YoY to INR136 crore on pricing, but Specialty Chemicals margins held above 25%, and management expects to do better than that threshold, with incremental margin reinvested in R&D and technical teams.
• What to watch next quarter: Whether the first CDMO shipments from Bharuch land on time and at committed volumes, whether the vitamin B3 price uptick holds, and whether the U.S. FTA unlocks the customer orders that had been deferred.

CDMO: The Pipeline Becomes a Production Reality

• The big plant is live: The agrochemical CDMO plant at Bharuch was commissioned on 5 January 2026 with the first batch charged; the first kilogram of final product is expected by mid-March, with shipments beginning in March itself.
• Visibility is confirmed for the near term: The customer has already provided volume visibility for at least the first few months, and the company expects to ramp to full production potential as soon as it starts.
• The molecule funnel keeps expanding: 5 new molecules were added in the last 3 months, bringing the confirmed pipeline to 16 molecules with a peak annual revenue potential exceeding INR1,400 crore. The broader opportunity funnel now spans more than 100 active opportunities, with 7-plus in advanced discussions.
• Peak revenue takes time: For most confirmed molecules, management estimates at least 3 to 4 years from confirmation to reach peak demand, so the revenue build will be gradual.
• Contractual risk is partially addressed: CDMO contracts where the company has invested heavily carry minimum volume offtake commitments from both sides, following typical industry norms, though management declined to discuss specific customer or molecule protections.
• The intermediate is export-linked: The large CDMO contract is an export order where the innovator converts the intermediate into the final molecule and can ship it globally, insulating Jubilant from end-market geography risk on that contract.
• Margin north of the threshold: Management declined to give specific profitability for the large agrochemical CDMO order but stated it will be "north of" the 20-25% EBITDA margin threshold discussed previously.

Deepak Jain: "5th of January, we did the puja at the plant and commissioned the first batch. It is a complex multistage product. So the whole cycle of producing even the first kg of final product is at least a six to eight weeks process... by mid-March, we are hoping we will get the first kg out and we will start shipments in March itself."

Pricing Cycle: Bottoming Out Across Portfolios

• The bottoming call: Management stated that across product categories, pricing has not seen any significant further decline in the last 6 months, and in a couple of areas there has been a marginal increase. The view is that pricing has bottomed out.
• Specialty Chemicals (pyridine derivatives): Pricing pressure was concentrated in the last two quarters of the calendar year and had a big impact on Q3 results, but some uptick has already been seen in certain pyridine derivatives.
• Nutrition (vitamin B3): Feed-grade pricing has been under pressure from intensified global competition, but a 7-8% price increase has appeared in the last few days. Management hopes it sustains in coming weeks.
• Acetyls (commodity): Prices have been deflated for the last couple of years and had bottomed out; acetic acid prices have seen an uptick in the last 2 months, and rising raw material costs point toward a gradual upward trend.
• Volume growth is outrunning price decline: For the first 9 months, volume and mix growth (more than double digit) exceeded pricing decline (high single digits), so Specialty Chemicals has grown on a year-to-date basis.
• China anti-involution policy: Management is watching China's anti-involution strategy as a potential catalyst to bring prices back, and says some uptick is already visible.

Deepak Jain: "The different product categories are at different stages of the cycle. But one thing we can see, we have bottomed out."

Trade Policy: FTAs as a Demand Unlock

• U.S. FTA signed, uncertainty removed: Some customers had slowed down booking of new orders due to uncertainty around the U.S. FTA, even on products not under any duty or tariff regime because of the long exemption list in Annexure 3. With the FTA now signed, that uncertainty is gone and orders are expected to resume.
• EU FTA as the next catalyst: Duties and tariffs of about 6-7% exist on a bunch of products for India (same as for China) in the EU market. As those duties go away, management expects competitiveness to increase, potentially driving volume and price upside starting next year.
• Choline as proof of concept: When the company gained a favorable tariff structure vis-a-vis Chinese competition, its share started to increase and volumes in the European market began booking, demonstrating the mechanism management expects to repeat.
• Execution timing on EU is vague: Management hopes the EU FTA will be executed "early next year," but no specific date was given.

Segment Performance

• Cost efficiency as a margin buffer: Power and fuel expenses were down 10% YoY and ~3% QoQ despite higher production volumes, driven by the commissioning of renewable O2 power at Bharuch. Renewable power share reached 34% in Q3 vs 28% in Q2.
• One-time labour provision: INR13 crore was provisioned for employee gratuity and leave encashment under New Labour Code amendments, a non-recurring drag on the quarter.
• Rupee movement is broadly neutral: The company is naturally hedged because it imports a lot of raw materials, particularly in acetyls and Specialty Chemicals, making it by and large agnostic to rupee depreciation at the overall company level.

Margin Outlook & Capital Allocation

• Specialty Chemicals margin ambition: Management believes it can "hopefully do better than 25%" EBITDA margin in Specialty Chemicals, helped by cost initiatives that were not built into the 5-year projection shared previously. Margins are expected to be maintained quarter-on-quarter and year-on-year.
• Incremental margin reinvested: Any margin upside will be reinvested in building capability in R&D and technical teams, as growing Specialty Chemicals remains the key focus area.
• Nutrition margin recovery path: The combined impact of the feed price uptick and cosmetic/food segment growth should "hopefully start reflecting in this quarter and definitely next quarter onwards." Scaling up utilization and volumes from the new Nutrition plant in FY27 is expected to lift margins further.
• Lean savings program on track: The INR120 crore-plus annual lean savings program remains firmly on track, providing a structural cost tailwind.
• Capex and balance sheet: The company plans to invest approximately INR500 crore in FY27, supported by internal accruals. Net debt-to-EBITDA improved to 0.94x from 1.24x in Q2 FY26.
• Multi-year aspiration: Management hopes to continue growing with EBITDA at a 20% CAGR on a multiyear average, while cautioning that any single year can be affected by many factors.

Deepak Jain: "I think we should hopefully be able to do better than 25% in Specialty Chemical EBITDA in Specialty Chemicals, which is what we have been maintaining."

CDMO Pipeline Breadth & Customer Diversification

• Five verticals, one funnel: The CDMO opportunity set spans agrochemicals, pharmaceuticals, nutrition, fine chemicals, and industrial applications. Management says its strength and relationships across these five segments enable it to create a diversified funnel.
• Agro innovator project starting: Beyond the large Bharuch contract, another agro innovator project is expected to begin dispatching volumes from March 2026.
• New capacity being built: Construction has begun on a new multipurpose plant at Gajraula, which will add flexibility and capacity for CDMO and fine chemicals, strengthening future readiness for upcoming projects.
• Customer concentration risk is present but undisclosed: When an analyst asked how a specific CDMO customer's guidance for continued pressures in its EPC diamide portfolio translates into volume visibility for Jubilant, management declined to answer, stating it never discloses CDMO molecule or customer names publicly.

Deepak Jain: "Given our strength, given our relationship with customers across these 5 key segments where we operate, we are able to get traction with the customers across the board and create the funnel."

Guidance & Commitments

Key Metrics